Leadership & Pay ·
On July 16, 2026, Harmony Biosciences reported preliminary Q2 2026 net product revenue for WAKIX of approximately $261…
HRMYHarmony Biosciences Holdings, Inc.
On July 16, 2026, Harmony Biosciences reported preliminary Q2 2026 net product revenue for WAKIX of approximately $261 million, a 30% increase year-over-year and a record quarterly result. The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion. Simultaneously, the company announced that CFO Glenn Reicin stepped down effective July 16, 2026, to pursue other opportunities. Stephen Mollichella, Senior Vice President and Controller, was appointed as Interim Principal Financial Officer. Full Q2 2026 financial results are scheduled for release on August 4, 2026. The company is a pharmaceutical company that develops and commercializes therapies for rare neurological diseases.